Xhance: payments to doctors
Payments that named Xhance as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $9.4M
- Providers
- 17,120
- Transactions
- 113,431
- Average per transaction
- $83
The per-transaction average — $83 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 17,120 providers the average total is $551, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Optinose US, Inc. | $9,372,673 | 99.3% |
| Paratek Pharmaceuticals, Inc. | $64,772 | 0.7% |
| Kaleo, Inc. | $1,253 | 0.0% |